Cisplatin, epirubicin, and lonidamine combination regimen as first-line chemotherapy for metastatic: Breast cancer: A pilot study

Cancer Chemotherapy and Pharmacology

Volumn 41, Issue 4, 1998, Pages 333-338

  Dogliotti, L ^a,g   Danese, S ^b   Berruti, A ^a   Zola, P ^b   Buniva, T ^a   Bottini, A ^c   Richiardi, G ^b   Moro, G ^d   Farris, A ^e   Bau M G ^b   Porcile, G ^f  

^a UNIVERSITY OF TURIN   (Italy)

^b Anna   (Italy)

^c Ist Osp   (Italy)

^d Ospedale di Biella   (Italy)

^e UNIVERSITY OF SASSARI   (Italy)

^f Ospedale di Alba   (Italy)

^g SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

Advanced breast cancer; Cisplatin; Epirubicin; Lonidamine; Toxicity

Indexed keywords

CISPLATIN; EPIRUBICIN; LONIDAMINE;

ADULT; AGED; ALOPECIA; ARTICLE; ASTHENIA; BLOOD TOXICITY; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MYALGIA; NAUSEA; PRIORITY JOURNAL; SEPTIC SHOCK; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CISPLATIN; EPIRUBICIN; FEMALE; HUMANS; INDAZOLES; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NAUSEA; PILOT PROJECTS; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031975799     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050747     Document Type: Article

References (31)

1. Bonadonna G, Gianni L, Santoro A, Bonfante V, Bidoli P, Casali P, Demicheli R, Valagussa P (1993) Drugs ten years later: epirubicin. Ann Oncol 4: 359-369
2. Sledge GW, Loehrer PJ, Roth BJ, Einhorn LH (1988) Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol 6: 1811-1814
3. Kolaric K, Roth A, Vukas D, Cervek J (1984) CAP (cyclophosphamide, Adriamycin, platinum) vs CMFVP (cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, prednisolone) combination chemotherapy in untreated metastatic breast cancer. A preliminary report of a controlled clinical study. Cancer Chemother Pharmacol 13: 142-144
4. Langer CJ, Catalano R, Saren B, Weiner LM, Comis RL (1991) Efficacy of M-VAC in advanced, measurable breast carcinoma: phase II pilot study. Proc Annu Meet Am Soc Clin Oncol 10: A134
5. Colozza M, Gori S, Mosconi M, Anastasi P, De Angelis V, Giansanti M, Mercati U, Aristei C, Latini P, Tonato M (1996) Induction chemotherapy with cisplatin, doxorubicin and cyclophosphamide (CAP) in a combined modality approach for locally advanced and inflammatory breast cancer. Am J Clin Oncol 19: 10-17
6. Ozols RF, Young RC (1991) Chemotherapy of ovarian cancer. Semin Oncol 18: 222-232
7. Preusser P, Wilke H, Achterrath W, Fink U, Lenaz L, Heinicke B, Meyer J, Meyer HJ, Buente H (1989) Phase II study with the combination etoposide, doxorubicin and cisplatin in advanced measurable gastric cancer. J Clin Oncol 7: 1310-1317
8. Cruciani G, Dazzi C, Montanari F, Voce S, Salerno V, Giannini M, Emiliani E, Marangolo M (1993) Conservative treatment for T2-T4 bladder cancer with primary chemotherapy and radiotherapy: a pilot study. Tumori 79: 53-57
9. Floridi A, Paggi MG, Marcante ML, Silvestrini B, Caputo A, De Martino C (1981) Lonidamine, a selective inhibitor of aerobic glycolisis of murine tumor cells. J Natl Cancer Inst 66: 497-499
10. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A (1981) Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666
11. 31C nuclear magnetic resonance studies. Cancer Res 55: 2814-2821
12. De Martino C, Malorni W, Accinni L, Rosati F, Nista A, Formisano G, Silvestrini B, Arancia G (1987) Cell membrane changes induced by lonidamine in human erythrocytes and T-lymphocytes, and Ehrlich ascites tumor cells. Exp Mol Pathol 46: 15-30
13. Rosbe KW, Brann TW, Holden SA, Teicher BA, Frei E III (1989) Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro. Cancer Chemother Pharmacol 25: 32-36
14. Silvestrini R, Zaffaroni N, Villa R, Orlandi L, Costa A (1992) Enhancement of cisplatin activity by lonidamine in human ovarian cancer cells. Int J Cancer 52: 813-817
15. Del Bufalo D, Zupi G (1994) In vitro potentiation of epirubicin activity by lonidamine in a human breast cancer cell line. Int J Oncol 4: 737-740
16. Zupi G, Greco C, Laudonio N, Benassi M, Silvestrini B, Caputo A (1986) In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. Anticancer Res 6: 1245-1250
17. Citro G, Cucco C, Verdina A, Zupi G (1991) Reversal of adriamycin resistance by lonidamine in a human breast cancer cell line. Br J Cancer 64: 534-536
18. Zupi G, Molinari A, D'Agnano I, Meschini S, Del Bufalo D, Matarrese P, Candiloro A, Calcabrini A, Citro G, Arancia G (1995) Adriamycin resistance modulation induced by lonidamine in human breast cancer cells. Anticancer Res 15: 2469-2478
19. Moraglio L, Brema F, Pastorino G, Martini MC, Vallauri M (1995) Combination of epirubicin and lonidamine for treatment of advanced breast cancer. Tumori 81: 107-111
20. Tomirotti M, Bernardo G, Epifani C, Biasioli R, Franchi R, Mensi F, Carnaghi P, Schieppati G, Scanni A (1993) Recovery of response to adriamycin and cyclophosphamide by lonidamine in previously treated metastatic breast cancer patients. Int J Oncol 3: 213-217
21. Calabresi F, Marolla P, Di Lauro L, Gallo Curcio C, Paoletti G, Lombardi A, Giannarelli D, Ballatore P, Foggi CM, Di Palma M, Stolfi R, Cortesi E (1994) Lonidamine as a potentiating agent of the FAC regimen in the treatment of advanced breast cancer. Results of a multicentric randomized clinical study. Int J Oncol 4: 753-760
22. Dogliotti L, Berruti A, Buniva T, Zola P, Baù MG, Farris A, Sarobba MG, Bottini A, Alquati P, Deltetto F, Gosso P, Monzeglio C, Moro G, Sussio M, Perroni D (1996) Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial. J Clin Oncol 14: 1165-1172
23. Amadori D, Frassineti GL, Nanni O, De Matteis A, Mustacchi G, Zoli W (1996) Lonidamine in modulation of response to doxorubicin in metastatic breast cancer patients. Proc Am Annu Soc Clin Oncol 15: A110
24. De Lena M, De Mitrio A, Catino AM, Lorusso V, Brandi M (1994) Recovery of response to platinum with lonidamine in previously treated metastatic ovarian cancer. Preliminary results. Int J Oncol 4: 779-782
25. Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Mastrantonio P, Barzelloni ML, Gesuè G, Mantovani G, Santangelo M (1994) Recovery of sensitivity to cisplatinum and epidoxorubicin by lonidamine and interferon in advanced ovarian cancer. Int J Oncol 4: 1265-1269
26. Gadducci A, Brunetti I, Muttini MP, Fanucchi A, Dargenio F, Giannessi PG, Conte PF (1994) Epidoxorubicin and lonidamine in refractory or recurrent epithelial ovarian cancer. Fur J Cancer 30A: 1432-1435
27. Silvestrini R, Gornati D, Zaffaroni N, Bearzatto A, De Marco C (1997) Modulation by lonidamine on the combined activity of cisplatin and epidoxorubicin in human breast cancer cells. Breast Cancer Res Treat 42: 103-112
28. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
29. Nie NH, Hull CH, Jeakins JG, Nourusis MJ (1988) Statistical package for the social sciences. SPSS, Chicago
30. Barberi-Heyob M, Griffon G, Merlin JL, Weber B (1993) Sequence-dependent growth-inhibitory effects of the in vivo combination of fluorouracil, cisplatin, and dypiridamole. Cancer Chemother Pharmacol 33: 163-170
31. Dogliotti L, Faggiuolo R, Berruti A, Antonacci R, Ortega C, Lancranjan J (1990) Prevention of nausea and vomiting in cisplatin-treated patients by a selective 5-hydroxytryptamine (5-HT3) receptor antagonist, ICS 205-930. Tumori 76: 595-598